CASI Pharmaceuticals (CASIF) Non-Current Assets (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Non-Current Assets came in at $12.2 million in Q4 2025, down 13.51% YoY from $14.1 million in Q4 2024, and down 2.82% on a QoQ basis from $12.5 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Non-Current Assets (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Non-Current Assets data on file, last reported at $12.2 million in Q4 2025.
- Quarterly Non-Current Assets fell 13.51% year-over-year to $12.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$27.1 billion (up 71.87% YoY) and the FY2025 annual result came in at $12.2 million, down 13.51% from the prior year.
- Non-Current Assets retreated to $12.2 million in Q4 2025, from $12.5 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $76.3 million in Q4 2021 to a low of -$61.0 billion in Q2 2023.
- A 5-year average of -$16.8 billion and a median of $12.5 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets sank 259925.22% — and 2025, when it soared 100.04%.
- Tracing CASIF's Non-Current Assets over 5 years: stood at $76.3 million in 2021, then slumped by 70.11% to $22.8 million in 2022, then slumped by 259925.22% to -$59.3 billion in 2023, then surged by 100.02% to $14.1 million in 2024, then retreated by 13.51% to $12.2 million in 2025.
- The last three Non-Current Assets figures came in at $12.2 million (Q4 2025), $12.5 million (Q3 2025), and $13.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | 11.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.19 Mn |
| Sep 30, 2025 | 12.55 Mn |
| Jun 30, 2025 | 13.04 Mn |
| Mar 31, 2025 | -27.16 Bn |
| Dec 31, 2024 | 14.10 Mn |
| Jun 30, 2024 | -37.20 Bn |
| Mar 31, 2024 | 14.86 Mn |
| Dec 31, 2023 | -59.27 Bn |
| Jun 30, 2023 | -61.00 Bn |
| Dec 31, 2022 | 22.81 Mn |
| Dec 31, 2021 | 76.33 Mn |